Recruiting Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance NCT05470504 Conditions Glucose Metabolism Disorders, Hyperinsulinism, Insulin Receptor Mutation, +5 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
